Skip to main content

Table 2 Lesion and procedural characteristics

From: Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes

  Overall BP-SES DP-EES p value
n = 165 n = 48 n = 117
Target vessel, n (%) 0.254
 Left main trunk 7 (4.2) 1 (2.1) 6 (5.1)
 Left anterior descending artery 86 (52.1) 25 (52.1) 61 (52.1)
 Left circumflex artery 20 (12.1) 3 (6.2) 17 (14.5)
 Right coronary artery 52 (31.6) 19 (39.6) 33 (28.3)
Type B2/C lesion, n (%) 92 (55.8) 30 (62.5) 62 (53.0) 0.264
QCA pre PCI
 Lesion length, mm 22.6 (12.7–35.1) 21.3 (12.2–37.9) 23.9 (13.5–35.0) 0.401
 Reference vessel diameter, mm 2.48 (2.07–2.98) 2.45 (2.11–2.81) 2.48 (2.06–3.02) 0.649
 Minimum lumen diameter, mm 0.87 (0.45–1.22) 0.78 (0.51–1.01) 0.91 (0.42–1.30) 0.410
 Diameter stenosis, % 64 (51–80) 69 (58–80) 63 (50–80) 0.405
QCA post PCI
 Reference vessel diameter, mm 2.63 (2.34–3.02) 2.67 (2.43–3.10) 2.60 (2.26–3.01) 0.321
 Minimum lumen diameter, mm 2.30 (2.02–2.60) 2.39 (2.05–2.75) 2.26 (2.01–2.57) 0.216
 Diameter stenosis, % 11 (5–18) 11 (5–17) 12 (5–18) 0.624
Rotational atherectomy, n (%) 12 (7.3) 2 (4.2) 10 (8.6) 0.325
Bifurcation, n (%) 38 (23.0) 13 (27.1) 25 (21.4) 0.428
Chronic total occlusion, n (%) 17 (10.3) 4 (8.3) 13 (11.1) 0.594
Imaging device, n (%) 165 (100) 48 (100) 117 (100)
Number of stents, n 1 (1–2) 2 (1–2) 1 (1–2) 0.100
Total stent length, mm 33 (23–56) 37 (27–62) 33 (21–54) 0.134
Minimum stent diameter, mm 2.75 (2.5–3.0) 2.5 (2.5–3.0) 2.75 (2.5–3.0) 0.468
  1. BP-SES biodegradable polymer sirolimus-eluting stent, DP-EES durable polymer everolimus-eluting stent, PCI percutaneous coronary intervention, QCA quantitative coronary angiography